ArticleAMB Express2025
Development of a Komagataella phaffii-based expression system for high-activity anti-SARS-CoV-2 neutralizing antibodies.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The growing need for rapid and cost-effective antibody production highlights the potential of Komagataella phaffii (syn. Pichia pastoris) as an alternative to mammalian systems. This study aimed to develop and optimize engineered scFvs (single-chain antibody fragments) against SARS-CoV-2 using K. phaffii. Four scFv formats, scFv-His, scFv-CH3-His, scFv-ZIP-His, and scFv-Fc, were evaluated for binding activity, neutraliation potency, expression yield, and in vivo stability. Among them, scFv-Fc demonstrated the best overall performance, with strong antigen binding (EC50 = 0.0034 µg/mL), effective neutralizing activity (IC50 = 0.570 µg/mL), and a prolonged serum half-life exceeding 5 days. Optimization of fermentation conditions increased its expression from 23 to 110 mg/L. These results demonstrate the feasibility of engineering scFv-based therapeutics using yeast systems and establish a framework for the rapid and economical production of next-generation antibody formats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.